BiotechTube
Home/CheMedImmune/John D. Klement, MD, Ph.D
JD

John D. Klement, MD, Ph.D

Chief Medical Officer

CheMedImmune

Therapeutic Areas

OncologyAutoimmune Diseases

CheMedImmune Pipeline

DrugIndicationPhase
OPN Blockade mAbs (100D3/103D6)Colorectal Cancer, Pancreatic CancerPre-clinical
IFNA2-LNP01Lung MetastasesPre-clinical
Epigenetic Dual TargetingColorectal Cancer (ICI-resistant)Pre-clinical

Leadership Team at CheMedImmune

PS
Priscilla S. Redd, PhD
Chief Executive Officer and Chief Scientific Officer
View full CheMedImmune profile